Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM457B1)

Drug Name
FK-888 Drug Info
Synonyms
FK 888; FK-888; 138449-07-7; FK888; N(2)-(4-Hydroxy-1-(1-methyl-1H-indol-3-yl)carbonyl-L-prolyl)-N-methyl-N-phenylmethyl-3-(2-naphthyl)-L-alaninamide; SCHEMBL8079679; GTPL2114; AC1L332N; CHEMBL1416993; CHEBI:93463; DTXSID70160680; MolPort-023-276-412; HMS3269A13; ZINC3926844; PDSP2_000648; AKOS024457076; NCGC00159560-01; L-Alaninamide, trans-4-hydroxy-1-((1-methyl-1H-indol-3-yl)carbonyl)-L-prolyl-N-methyl-3-(2-naphthalenyl)-N-(phenylmethyl)-; LS-193299; BRD-K83508485-001-01-9
Cross-matching ID
PubChem CID
107967
ChEBI ID
CHEMBL93463
CAS Number
CAS 138449-07-7
TTD Drug ID
D05UKK

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Arginine and proline metabolism 1.94 1.38e-2 39/50 (78%) MAOA;ALDH4A1;ALDH9A1;...
Retinol metabolism -1.67 2.96e-2 41/68 (60.29%) UGT2A3;CYP1A1;CYP2C9;...
Chagas disease -1.68 2.68e-2 93/102 (91.18%) SMAD2;CASP8;MAPK14;...
C-type lectin receptor signaling pathway -1.70 2.34e-2 93/104 (89.42%) PLK3;CASP8;MAPK14;...
Cellular senescence -1.70 2.29e-2 139/156 (89.1%) PPP1CA;MAP2K3;CHEK1;...
Viral protein interaction with cytokine and cytokine re... -1.70 2.37e-2 84/100 (84%) IL24;CXCR2;IL10;...
Mineral absorption -1.72 1.97e-2 48/60 (80%) ATOX1;TF;ATP7A;...
TGF-beta signaling pathway -1.72 1.95e-2 81/94 (86.17%) BMPR2;SMAD4;SMAD5;...
TNF signaling pathway -1.72 2.04e-2 103/112 (91.96%) MAPK8;CREB5;MAP2K3;...
Tuberculosis -1.73 2.08e-2 159/180 (88.33%) CALML3;MRC2;IFNGR1;...
Basal cell carcinoma -1.73 2.17e-2 41/63 (65.08%) FZD1;GADD45G;AXIN1;...
Hepatitis B -1.74 2.10e-2 151/162 (93.21%) STAT2;RELA;STAT5B;...
Yersinia infection -1.74 2.01e-2 120/137 (87.59%) MAPK14;PIP5K1A;LCP2;...
Leishmaniasis -1.74 1.99e-2 67/77 (87.01%) HLA-DRB1;FOS;IL1A;...
Pertussis -1.75 2.10e-2 64/76 (84.21%) IL10;C1QB;ITGB2;...
Neutrophil extracellular trap formation -1.75 2.01e-2 101/189 (53.44%) PLCG1;SRC;SELP;...
Viral myocarditis -1.75 2.14e-2 53/60 (88.33%) EIF4G1;ITGB2;ACTB;...
Intestinal immune network for IgA production -1.76 1.85e-2 38/48 (79.17%) PIGR;ICOSLG;HLA-DOB;...
Human T-cell leukemia virus 1 infection -1.80 1.52e-2 197/219 (89.95%) MAPK8;CANX;ELK4;...
Malaria -1.80 1.65e-2 44/50 (88%) GYPA;IL10;ITGB2;...
Colorectal cancer -1.82 1.12e-2 84/86 (97.67%) SMAD3;EGFR;GADD45G;...
NOD-like receptor signaling pathway -1.83 1.11e-2 145/181 (80.11%) HSP90AA1;CASP8;MAPK14;...
Toxoplasmosis -1.84 9.60e-3 103/112 (91.96%) HLA-DOA;NFKB1;TLR2;...
Cytokine-cytokine receptor interaction -1.85 1.08e-2 246/295 (83.39%) CXCR3;TNFSF8;CX3CL1;...
NF-kappa B signaling pathway -1.85 7.05e-3 90/104 (86.54%) CD40LG;TNFSF11;CXCL12;...
Osteoclast differentiation -1.89 4.11e-3 117/127 (92.13%) LILRA2;MAPK8;FCGR2B;...
Rheumatoid arthritis -1.89 4.94e-3 78/93 (83.87%) ANGPT1;CSF1;TNFRSF11A;...
Inflammatory bowel disease -2.03 0.00e+0 58/65 (89.23%) IFNGR1;HLA-DMB;SMAD2;...
Hematopoietic cell lineage -2.04 0.00e+0 90/99 (90.91%) CD34;CSF3R;GYPA;...
Toll-like receptor signaling pathway -2.08 0.00e+0 94/104 (90.38%) TLR8;RIPK1;NFKB1;...
Th17 cell differentiation -2.11 0.00e+0 95/107 (88.79%) MAPK8;CD4;SMAD4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 10uM 24H